WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526599
CAS#: 88475-69-8 (sodium)
Description: Beraprost sodium is a potent IP receptor agonist, inhibiting ADP-induced platelet aggregation and P-selectin expression. Beraprost sodium (BPS) is a stable orally active prostacyclin analogue with vasodilatory and anti-platelet effects, and has been widely used as therapeutics for pulmonary artery hypertension and chronic arterial obstruction.
Hodoodo Cat#: H526599
Name: Beraprost sodium
CAS#: 88475-69-8 (sodium)
Chemical Formula: C24H29NaO5
Exact Mass: 0.00
Molecular Weight: 420.481
Elemental Analysis: C, 68.56; H, 6.95; Na, 5.47; O, 19.02
Related CAS #: 88430-50-6 (free acid) 88475-69-8 (sodium)
Synonym: Beraprost sodium; ML 1129; ML-1129; ML1129; Procyclin; TRK 100; TRK-100; TRK100;
IUPAC/Chemical Name: 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid, monosodium salt
InChi Key: YTCZZXIRLARSET-UEIGIMKUSA-M
InChi Code: InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;
SMILES Code: O=C([O-])CCCC1=C(OC2C3C(/C=C/C(O)C(C)CC#CC)C(O)C2)C3=CC=C1.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Beraprost sodium is a potent IP receptor agonist which inhibits ADP-induced platelet aggregation and P-selectin expression. |
| In vitro activity: | Beraprost sodium treatment increased the expression of hepatic SIRT1 and peroxisome proliferator activated receptor α (PPARα) in human-derived HepG2 cells treated with fructose. These effects were blocked in HepG2 cells after transfection with siRNA against SIRT1. MiR-200a was highly expressed during fructose treatment and was down regulated by beraprost sodium (P<0.05). A luciferase assay showed that miR-200a regulated SIRT1 by binding to the 3' UTR. Overexpression of miR-200a inhibited expression of hepatic SIRT1. These results demonstrated that SIRT1 pathway mediated the effects of beraprost sodium on attenuation of hepatic lipid disorders induced by fructose and revealed the primary role of miR-200a in the regulation of hepatic SIRT1 by beraprost sodium. Reference: Metabolism. 2017 Aug;73:9-21. https://www.metabolismjournal.com/article/S0026-0495(17)30144-0/fulltext |
| In vivo activity: | Beraprost sodium, a stable prostacyclin analog, was showed to improve survival rates in two different rat models, anti-glomerular basement membrane (GBM) glomerulonephritis (GN) and 5/6 nephrectomized (Nx) chronic kidney disease (CKD) rats. In the anti-GBM rat, beraprost sodium (0.2 and 0.6 mg/kg/day) improved survival rate (hazard ratio for beraprost sodium 0.6 mg/kg/day group, 0.10; 95% confidence interval, 0.01 to 0.68). Subsequently, in the 5/6 Nx CKD rat, beraprost sodium (0.6 mg/kg/day) improved survival rate (hazard ratio for beraprost sodium, 0.46; 95% confidence interval, 0.23 to 0.92), serum creatinine doubling time and the slope of the reciprocal of serum creatinine. Reference: Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. https://www.sciencedirect.com/science/article/abs/pii/S0014299913005542?via%3Dihub |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 77.0 | 183.12 | |
| Ethanol | 20.0 | 47.56 | |
| PBS (pH 7.2) | 19.0 | 45.19 |
The following data is based on the product molecular weight 420.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Zhang P, Xu L, Guan H, Liu L, Liu J, Huang Z, Cao X, Liao Z, Xiao H, Li Y. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism. 2017 Aug;73:9-21. doi: 10.1016/j.metabol.2017.05.003. Epub 2017 May 11. PMID: 28732575. 2. Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo B, Liu C, Sun D. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl). 2019 Jun;97(6):777-791. doi: 10.1007/s00109-019-01769-x. Epub 2019 Mar 28. PMID: 30923844. 3. Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, Okazaki S, Matsuura H, Fujii S, Matsuda F, Goto Y, Mochizuki H, Kurumatani H, Miyamoto M. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. Epub 2013 Jul 30. PMID: 23911885. |
| In vitro protocol: | 1. Zhang P, Xu L, Guan H, Liu L, Liu J, Huang Z, Cao X, Liao Z, Xiao H, Li Y. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism. 2017 Aug;73:9-21. doi: 10.1016/j.metabol.2017.05.003. Epub 2017 May 11. PMID: 28732575. 2. Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo B, Liu C, Sun D. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl). 2019 Jun;97(6):777-791. doi: 10.1007/s00109-019-01769-x. Epub 2019 Mar 28. PMID: 30923844. |
| In vivo protocol: | 1. Zhang P, Xu L, Guan H, Liu L, Liu J, Huang Z, Cao X, Liao Z, Xiao H, Li Y. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism. 2017 Aug;73:9-21. doi: 10.1016/j.metabol.2017.05.003. Epub 2017 May 11. PMID: 28732575. 2. Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, Okazaki S, Matsuura H, Fujii S, Matsuda F, Goto Y, Mochizuki H, Kurumatani H, Miyamoto M. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. Epub 2013 Jul 30. PMID: 23911885. |
1: Suzuki R, Yuchi Y, Saito T, Yasumura Y, Teshima T, Matsumoto H, Koyama H. Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function. Animals (Basel). 2022 Aug 15;12(16):2078. doi: 10.3390/ani12162078. PMID: 36009668; PMCID: PMC9405226.
2: Sugawara A, Kudo M, Saito A, Matsuda K, Uruno A, Ito S. Novel effects of beraprost sodium on vasculatures. Int Angiol. 2010 Apr;29(2 Suppl):28-32. PMID: 20357746.
3: Nowrouzi-Sohrabi P, Tabrizi R, Hessami K, Shabani-Borujeni M, Hosseini- Bensenjan M, Rezaei S, Jalali M, Keshavarz P, Ahmadizar F. The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials. Int Urol Nephrol. 2022 Jan;54(1):111-120. doi: 10.1007/s11255-021-02887-7. Epub 2021 May 21. PMID: 34019221.
4: Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, Okazaki S, Matsuura H, Fujii S, Matsuda F, Goto Y, Mochizuki H, Kurumatani H, Miyamoto M. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. Epub 2013 Jul 30. PMID: 23911885.
5: Suzuki R, Yuchi Y, Saito T, Teshima T, Matsumoto H, Koyama H. Investigation of Beraprost Sodium on Cardiac Function and Hemodynamics in Canine Models of Chronic Pulmonary Hypertension. Front Vet Sci. 2022 Apr 14;9:876178. doi: 10.3389/fvets.2022.876178. PMID: 35498754; PMCID: PMC9048895.
6: Nishio S, Nagase H, Kanou K, Aoki S, Kanbayashi Y. [Research and development of beraprost sodium, a new stable PGI2 analogue]. Yakugaku Zasshi. 1997 Aug;117(8):509-21. Japanese. doi: 10.1248/yakushi1947.117.8_509. PMID: 9306726.
7: Nishio S, Kurumatani H. [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue]. Nihon Yakurigaku Zasshi. 2001 Feb;117(2):123-30. Japanese. doi: 10.1254/fpj.117.123. PMID: 11233303.
8: Zhou J, Jiang S, Li Z, Li W. Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study. Diabetes Ther. 2023 Mar;14(3):497-506. doi: 10.1007/s13300-022-01361-6. Epub 2023 Jan 5. Erratum in: Diabetes Ther. 2023 Feb 8;: PMID: 36602671; PMCID: PMC9981824.
9: Zhang P, Xu L, Guan H, Liu L, Liu J, Huang Z, Cao X, Liao Z, Xiao H, Li Y. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism. 2017 Aug;73:9-21. doi: 10.1016/j.metabol.2017.05.003. Epub 2017 May 11. PMID: 28732575.
10: Hashiguchi M, Ohno K, Saito R. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi. 2004 Jun;124(6):321-32. doi: 10.1248/yakushi.124.321. PMID: 15170067.
11: Otsuki M, Goya K, Kasayama S. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vasc Health Risk Manag. 2005;1(3):209-15. PMID: 17319106; PMCID: PMC1993948.
12: Vicil S, Erdoğan S. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells. Turk J Med Sci. 2015;45(2):284-90. doi: 10.3906/sag-1401-108. PMID: 26084116.
13: Nakura M, Miyashita T, Yamamoto Y, Takada S, Kanou S, Tajima H, Takamura H, Ohta T. Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome. Anticancer Res. 2020 Sep;40(9):5171-5180. doi: 10.21873/anticanres.14520. PMID: 32878805.
14: Awsakulsutthi S, Punpho K, Mamom J, Baikrut P, Yingchoorod P. Beraprost sodium for chronic diabetic foot ulcer: a randomized controlled trial in thammasat university hospital. Ann Vasc Dis. 2014;7(1):40-5. doi: 10.3400/avd.oa.13-00092. Epub 2014 Feb 28. PMID: 24719661; PMCID: PMC3968414.
15: Ono S, Nagaoka T, Omae T, Tanano I, Kamiya T, Otani S, Ishibazawa A, Yoshida A. Beraprost sodium, a stable prostacyclin analogue, elicits dilation of isolated porcine retinal arterioles: roles of eNOS and potassium channels. Invest Ophthalmol Vis Sci. 2014 Jul 31;55(9):5752-9. doi: 10.1167/iovs.14-14902. PMID: 25082887.
16: Kim M, Kim JU, Kim SM, Kim H. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. Int Urol Nephrol. 2017 Jul;49(7):1287-1295. doi: 10.1007/s11255-017-1586-y. Epub 2017 Apr 13. PMID: 28409403.
17: Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo B, Liu C, Sun D. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl). 2019 Jun;97(6):777-791. doi: 10.1007/s00109-019-01769-x. Epub 2019 Mar 28. PMID: 30923844.
18: Sun D, Yang W, Wang Z, Gao B. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension. Med Sci Monit. 2021 Feb 3;27:e928413. doi: 10.12659/MSM.928413. PMID: 33531453; PMCID: PMC7869411.
19: Pan Y, Yu L, Lei W, Guo Y, Wang J, Yu H, Tang Y, Yang J. Beraprost sodium protects against chronic brain injury in aluminum-overload rats. Behav Brain Funct. 2015 Feb 7;11(1):6. doi: 10.1186/s12993-014-0051-7. PMID: 25888780; PMCID: PMC4326490.
20: Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med. 2002 Sep;8(9):546-50. PMID: 12456993; PMCID: PMC2040016.
